Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 25;23(1):385-394.
doi: 10.1007/s40200-024-01406-6. eCollection 2024 Jun.

Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes

John Andraos  1 , Shawn R Smith  1 , Amanda Tran  2 , David Q Pham  1   2
Affiliations
Review

Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes

John Andraos et al. J Diabetes Metab Disord. .

Abstract

Purpose: Metformin has been the first-line treatment for type 2 diabetes mellitus as monotherapy or concomitantly with other glucose-lowering therapies due to its efficacy, safety, and affordability. Recent studies on the cardioprotective and renoprotective benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have influenced guidelines on diabetes management to consider these newer agents as alternative first-line therapies. This paper explores the literature supporting the use of these newer medications alone as a first-line agent in place of metformin.

Methods: A review of citations from the most recent guidelines along with a literature search via PubMed was completed to review (1) what, historically, made metformin first-line (2) if newer agents' benefits remain when used without metformin (3) how newer agents compare against metformin when used without it.

Results: Evaluation of the historical literature was completed to summarize the key findings that support metformin as a first-line therapy agent. Additionally, an assessment of the literature reveals that the benefits of these two newer classes are independent of concomitant metformin therapy. Finally, studies have demonstrated that these newer agents can be either non-inferior or sometimes superior to metformin when used as monotherapy.

Conclusion: GLP-1 RA and SGLT-2i can be considered as first line monotherapies for select patients with high cardiovascular risks, renal disease, or weight loss requirements. However, pharmacoeconomic considerations along with lesser long-term safety outcomes should limit these agents' use in certain patients as the management of diabetes continues to transition towards shared-decision making.

Supplementary information: The online version contains supplementary material available at 10.1007/s40200-024-01406-6.

Keywords: GLP-1 receptor agonists; Metformin; SGLT-2 inhibitors; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestAuthors do not have any conflicts of interests, financial or otherwise, related to this article.

References

    1. IDF Clinical Guidelines Task Force Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23:579–93. doi: 10.1111/j.1464-5491.2006.01918.x. - DOI - PubMed
    1. American Diabetes Association Standards of medical care in diabetes–2006. Diabetes Care. 2006;29(suppl1):4–s42. doi: 10.2337/diacare.29.s1.06.s4. - DOI
    1. Effect of intensive Blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (Ukpds) Group. Lancet. 1998;352(9131):854–65. doi: 10.1016/S0140-6736(98)07037-8. - DOI - PubMed
    1. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm– 2020 executive summary. Endocr Pract. 2020;26(1):107–39. doi: 10.4158/CS-2019-0472. - DOI - PubMed
    1. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. doi: 10.1093/eurheartj/ehz486. - DOI - PubMed

LinkOut - more resources